Phibro Animal Health Q4 net sales up 39% to $378.7M; FY2026 guidance sees 25% adj. EBITDA growth

PHIBRO ANIMAL HEALTH CORP

2025-FY EPS reported $1.19 revenue$1,296,215,000

Q4 net sales $378.7M (+39% YoY), net income $17.2M vs $0.8M, adj. diluted EPS $0.57 (+39%).
FY net sales $1,296.2M (+27%), adj. EBITDA $183.7M (+65%), adj. diluted EPS $2.09 (+76%).
Zoetis MFA portfolio contributed $94.5M incremental revenue in Q4 and $208.2M for full year.
FY2026 guidance: net sales $1.43-1.48B, adj. EBITDA $225-235M (25% growth), adj. EPS $2.52-2.70.
Gross leverage 3.1x as of June 30, 2025; free cash flow $41.8M for the year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.